Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Comment by ledrogon Apr 16, 2019 11:35pm
121 Views
Post# 29637121

RE:LED

RE:LEDGiven that Zenith is not a publicly traded company I believe the disclosure rules are not as stringent...but yes, that was back in May of 2018 at Bloom Burton in Toronto,

He told me of a deal for Zenith and I was left with the unmistakable impression that something would be announced in the next (back then) 2 to 3 months.....further he believed that Zenith investors would likely put some of the proceeds of this deal that never happened into Resverlogix.

I just did a SA blog post that deals with this whole issue of setting and failing to meet expectations....

The latest is that BETonMACE will hit 250 events and wrap up the trial this month...stated by Don himself during the Roth Conference, and picked up by the company's paid for Zack's analyst John Vandermosten.  

Frankly I'm not expecting them to announce 250 events in April, and quite honestly it ticks me off to no end.  This kind of merde has been going on too long and has been happening too often for me to believe it is anything other than intentional:

https://seekingalpha.com/instablog/15663412-joe_retail/5293961-resverlogix-trying-annoy-retail-shareholders
Bullboard Posts